Diagnosing autoimmune disorders is challenging due to diverse symptoms and unpredictable progression.
KREX technology simplifies this process with advanced autoantibody profiling, uncovering reliable biomarkers that appear early in disease for earlier, more accurate diagnoses and personalized treatment.
Despite advancements in targeted cancer therapies, improved screening tools are essential to match patients with effective treatments while reducing side effects. KREX technology meets this need by profiling autoantibodies produced in response to tumor antigens. These unique signatures help identify treatment responders, predict adverse risks, and support more personalized, effective cancer care.
Neurological diseases are notoriously complex to diagnose and treat due to triggers like infections, brain injuries, or autoimmunity. With drug development failure rates exceeding 90%, reliable biomarkers are essential. KREX technology uncovers biomarkers for diagnosis and patient stratification, particularly in conditions with inflammatory or autoimmune components – advancing precision medicine in neurological care.
Infectious diseases and the immune system are inherently linked, with infections sometimes triggering or worsening autoimmune reactions. KREX technology enables high-precision profiling of antibodies and autoantibodies, making it essential for monitoring pathogen exposure, evaluating vaccine efficacy, and understanding the humoral immune response after infection.
Autoantibodies – or antibodies that target the body’s own proteins – serving serve as powerful biomarkers for early detection and timely intervention. With
KREX antibody profiling, you can discover biomarker signatures that bring us closer to earlier diagnosis and more personalized patient care.
Elevated antibody levels reflect the immune response to disease and can indicate future risk, even in healthy individuals. Identifying these biomarkers enables proactive monitoring, supporting early diagnosis and timely intervention to improve outcomes. With KREX technology, you gain the insights needed to stay ahead of disease and enable preventive care.
KREX technology reveals distinct disease subtypes, enabling precise patient stratification and personalized treatments. By uncovering molecular differences within patient groups, antibody profiling accelerates targeted therapy development, improves outcomes, and advances precision medicine.
KREX antibody profiling identifies biomarkers that predict treatment responses or adverse events, enabling safer, personalized care. These insights optimize therapeutic strategies for better patient outcomes.
Antibody profiling with KREX technology uncovers key antibodies and protein antigens involved in disease pathways and immune responses. These insights drive the identification of novel therapeutic targets, optimize drug and vaccine design, and guide patient selection for clinical trials. By accelerating development and improving success rates, KREX technology empowers you to advance therapeutics and vaccines with precision.